A study in healthy volunteers to assess safety and blood levels of AZD9742 after multiple doses over 14 days

Study identifier:D2690C00002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Single Center, Double-blind Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Intravenous AZD9742 after Administration of Multiple Ascending Doses for 14 days in Healthy Male and Female Subjects

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD9742, Placebo

Sex

All

Actual Enrollment

Study type

Interventional

Age

23 Years - 45 Years

Date

Study Start Date: 01 Feb 2010

Primary Completion Date: 01 Aug 2010

Study Completion Date: 01 Aug 2010

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Overland Park, KS, United States

Arms	Assigned Interventions
Experimental: 1	Drug: AZD9742 IV infusion, 15 days
Placebo Comparator: 2	Drug: Placebo IV infusion, 15 days

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1287&filename=CSR-D2690C00002.pdf
Download
CSR-D2690C00002.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

Quntiles- Overland Park Kansas

1-800-292-5533

volunteer@quintiles.com

Investigators

Principal Investigator

Andrew Shaw

AstraZeneca